Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...

Patients with a form of breast cancer in England will be offered a new treatment after it was given the green light for NHS use. Olaparib will offer the chance of ‘longer, healthier lives’ for ...

The appraisal committee has prepared final draft guidance (FDG) on olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336] and ...